Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

R. Saso, S. Kulkarni, P. Mitchell, J. Treleaven*, G. J. Swansbury, J. Mehta, R. Powles, S. Ashley, A. Kuan, T. Powles

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence of developing MDS/AML after MMM or MM chemotherapy was 15 per 100,000 patient years followup, while the actuarial risk was 1.1% and 1.6% at 5 and 10 years respectively. MTZ-based regimens carry a 10 x higher risk of subsequent MDS/AML compared to that seen in the general population. (C) 2000 Cancer Research Campaign.

Original languageEnglish (US)
Pages (from-to)91-94
Number of pages4
JournalBritish Journal of Cancer
Volume83
Issue number1
DOIs
StatePublished - 2000

Keywords

  • Acute myeloid leukaemia
  • Breast cancer
  • Mitoxantrone
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma'. Together they form a unique fingerprint.

Cite this